RALLIS CHRIS A 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Apr 11, 2025
Insider Transaction Report
Form 4
RALLIS CHRIS A
Director
Transactions
- Sale
Common Shares
2025-04-11$4.95/sh−1,409$6,975→ 53,784 total - Exercise/Conversion
Common Shares
2025-04-11$2.30/sh−2,173$4,998→ 180,533 totalExercise: $2.30From: 2015-05-11Exp: 2025-05-11→ Options (2,173 underlying) - Exercise/Conversion
Common Shares
2025-04-11$2.30/sh+2,173$4,998→ 55,193 total
Footnotes (3)
- [F1]. Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
- [F2]Shares sold to satisfy tax obligation on option exercise.
- [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.